BPC-157 vs Tirzepatide (Mounjaro / Zepbound)
Both are used for gut health. Here's how they compare on human evidence, mechanism, safety and availability — in plain English.
| BPC-157 | Tirzepatide (Mounjaro / Zepbound) | |
|---|---|---|
| Human evidence | ★★★☆☆ | ★★★★★ |
| Legal status | Not Approved | Prescription |
| How it works | A 15-amino-acid fragment of a gastric protein. Two characterised pathways: (1) upregulates VEGFR2 (KDR) → PI3K/Akt → eNOS (NOS3), driving angiogenesis (new blood vessels to injured tissue); (2) a Src–Caveolin-1–eNOS route. It also… | Dual agonist of GIPR (GIP receptor) and GLP1R. GIP receptor activation in the hypothalamus and adipose tissue synergises with GLP-1, producing greater appetite suppression and fat loss than GLP-1 alone. |
| In plain English | It tells injured tissue to grow a fresh blood supply (via the VEGFR2 switch), and blood flow is what healing runs on — so tendons, ligaments, gut lining and muscle appear to mend faster. The catch: almost all the evidence is in rats. Human… | Hits two "I'm full" gut-hormone switches at once instead of one — so it works even better. SURMOUNT-1: 22.5% bodyweight lost, approaching bariatric-surgery territory. |
| Bottom line | The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. | Currently the most effective approved obesity drug. |
| Availability | Not widely approved | Prescription only |
Which is better for gut health?
Tirzepatide (Mounjaro / Zepbound) has the stronger human-evidence rating (★★★★★ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
Full breakdowns: BPC-157 · Tirzepatide (Mounjaro / Zepbound).
Common questions
Is BPC-157 or Tirzepatide (Mounjaro / Zepbound) better for gut health?
Tirzepatide (Mounjaro / Zepbound) has the stronger human-evidence rating (★★★★★ vs ★★★☆☆), but the right choice still depends on your goal, tolerance and budget.
What's the difference between BPC-157 and Tirzepatide (Mounjaro / Zepbound)?
BPC-157: The most promising healing peptide by animal data — and the biggest human-evidence gap. Watch the July 2026 PCAC decision. — Tirzepatide (Mounjaro / Zepbound): Currently the most effective approved obesity drug.